Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003087 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target

NCT00003087: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00003087 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003087, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with radiation therapy before surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and surgery in treating patients with cancer of the esophagus that can be surgically removed.

Interventions

  • DRUG cisplatin
  • DRUG paclitaxel
  • RADIATION radiation therapy
  • PROCEDURE surgical procedure

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 1997-08
Est. Completion 2005-02
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT00003087

The ClinicalTrials.gov registry entry for NCT00003087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.

NCT00003087 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00003087 about?

NCT00003087 is a clinical study titled "Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with radiation therapy before surgery may kill more tumor cells. PURPOSE: Phase II tr...

What is the current status of trial NCT00003087?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1997-08. Estimated completion is 2005-02.

What interventions are being tested in trial NCT00003087?

The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), surgical procedure (PROCEDURE).

Who is sponsoring clinical trial NCT00003087?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.